Provided by Tiger Fintech (Singapore) Pte. Ltd.

Bioventus Inc.

7.56
+0.13001.75%
Post-market: 7.560.00000.00%16:05 EDT
Volume:493.05K
Turnover:3.70M
Market Cap:500.70M
PE:-14.55
High:7.62
Open:7.41
Low:7.35
Close:7.43
Loading ...

With 32% ownership, Bioventus Inc. (NASDAQ:BVS) has piqued the interest of institutional investors

Simply Wall St.
·
31 Jan

Australian Ethical Investment Ceases Substantial Holding in Bravura Solutions

TIPRANKS
·
30 Jan

With 38% stake, Bravura Solutions Limited (ASX:BVS) seems to have captured institutional investors' interest

Simply Wall St.
·
25 Jan

Bravura Solutions Announces $73.2 Million Capital Return to Shareholders

TIPRANKS
·
15 Jan

Australian Ethical Investment Adjusts Stake in Bravura Solutions

TIPRANKS
·
14 Jan

Bravura Solutions Announces Capital Return to Shareholders

TIPRANKS
·
13 Jan

BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business

Zacks
·
03 Jan

Analysts Offer Insights on Healthcare Companies: Bioventus (BVS), Corvus Pharmaceuticals (CRVS) and Lifecore Biomedical (LFCR)

TIPRANKS
·
02 Jan

Bioventus Sells Advanced Rehabilitation Business to Accelmed Partners

MT Newswires Live
·
02 Jan

Bioventus completes divestiture of its Advanced Rehabilitation business

TIPRANKS
·
02 Jan

Bioventus Completes Divestiture of Its Advanced Rehabilitation Business to Accelmed Partners

THOMSON REUTERS
·
02 Jan

Is Bioventus (BVS) Outperforming Other Medical Stocks This Year?

Zacks
·
23 Dec 2024

Bravura Solutions Restructures for Regional Focus

TIPRANKS
·
20 Dec 2024

Bravura Solutions Issues Unquoted Employee Securities

TIPRANKS
·
19 Dec 2024

Bravura Solutions Restructures Shareholding with Gran Fondo Capital

TIPRANKS
·
18 Dec 2024

BUZZ-J.P.Morgan upgrades Bioventus to 'neutral' on improved growth visibility, execution

Reuters
·
18 Dec 2024

JPMorgan Upgrades Bioventus to Neutral From Underweight, Adjusts Price Target to $13 From $12

MT Newswires Live
·
17 Dec 2024

Bioventus Raised to Neutral From Underweight by JP Morgan

Dow Jones
·
17 Dec 2024

Bioventus upgraded to Neutral from Underweight at JPMorgan

TIPRANKS
·
17 Dec 2024

Bioventus: Strategic Moves Amidst Financial Challenges Justify Hold Rating

TIPRANKS
·
17 Dec 2024